{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:18:53Z","timestamp":1792592333873,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Systemic lupus erythematosus (SLE) and autoimmune hepatitis (AIH) are distinct autoimmune disorders whose concurrent presentation (overlap syndrome) poses significant diagnostic and therapeutic challenges. While SLE-associated liver involvement is recognized, true SLE-AIH overlap is rare and lacks established management guidelines. This report details the successful management of such a case to contribute insights into this complex clinical scenario.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 35-year-old male presented with a 1-year history of intermittent facial and body rashes accompanied by significant weight loss (approximately 10\u2009kg). Over the preceding half-month, he developed signs of liver injury, including fatigue, cold intolerance, loss of appetite, and generalized weakness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Comprehensive diagnostic evaluation, cutaneous manifestations: facial and generalized skin rash, hematologic abnormalities: cytopenia, including serological testing (positive antinuclear antibody [1:1000], anti-SS-A antibodies, elevated immunoglobulin G, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein, decreased complement C3 and C4 levels), liver function tests (persistently elevated alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, globulin), and imaging (uneven liver texture\/density on ultrasound\/computed tomography), confirmed a diagnosis of SLE complicated by AIH. The diagnosis of SLE meets both the 1997 American College of Rheumatology classification criteria and the 2012 Systemic Lupus International Collaborating Clinics revised criteria. AIH diagnosis was supported by both the 1990 (score=16) and 2008 (score=7) International Autoimmune Hepatitis Group (IAIHG) scoring systems. Infectious and other common causes of liver injury were excluded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Initial management focused on controlling liver injury using intravenous and oral hepatoprotective agents (inosine, bicyclol, silibinin, compound glycyrrhizin, magnesium isoglycyrrhizinate). High-dose intravenous glucocorticoids (dexamethasone 5\u201310\u2009mg daily) were initiated concurrently to suppress autoimmune activity. Upon stabilization of liver function, treatment transitioned to oral prednisone (30\u2009mg daily) combined with the immunosuppressant leflunomide (10\u2009mg daily). Glucocorticoids were subsequently tapered strictly according to plan, while leflunomide monotherapy was maintained long-term. Adjunctive therapies included calcium and gastric protection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Liver function tests normalized following the combined hepatoprotective and glucocorticoid therapy. The introduction and maintenance of leflunomide, alongside glucocorticoid tapering, effectively controlled SLE disease activity. At a 2-year follow-up, the patient remained clinically stable with normalized liver function, no recurrence of severe symptoms, and a good quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case highlights the efficacy of a sequential treatment approach combining glucocorticoids and immunosuppressants (specifically leflunomide) for managing SLE-AIH overlap syndrome. Early diagnosis using established criteria is crucial. Multidisciplinary collaboration is essential. Long-term leflunomide monotherapy demonstrated sustained remission in this patient, although vigilance for adverse effects (e.g., hepatotoxicity) and disease flare is necessary. The absence of specific guidelines for this overlap syndrome underscores the need for individualized treatment strategies based on SLE and AIH management principles.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000043570","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:02:44Z","timestamp":1754089364000},"page":"e43570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of systemic lupus erythemus overlap syndrome with autoimmune hepatitis using a combination of glucocorticoids and immunosuppressive agents: Case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Zhijie","family":"Li","sequence":"first","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Zha","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jingzhou Traditional Chinese Medicine Hospital, Jingzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"},{"name":"Hubei Shizhen Laboratory, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhai","family":"Li","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"},{"name":"Hubei Shizhen Laboratory, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"},{"name":"Hubei Shizhen Laboratory, Wuhan, China"},{"name":"Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Liver and Kidney Research and Application of Traditional Chinese Medicine, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2753-5506","authenticated-orcid":false,"given":"Lianmei","family":"Lin","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine, Wuhan, China"},{"name":"Hubei Shizhen Laboratory, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults.","volume":"393","author":"Donatella","year":"2019","journal-title":"Lancet"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus.","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","article-title":"Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis.","volume":"19","author":"Lamba","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/hepr.13342","article-title":"Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan.","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"R5-20250918","first-page":"1","article-title":"Serum immunoglobulin g levels predict biochemical and histological remission of autoimmune hepatitis type 1: a single-center experience and literature review.","volume":"62","author":"Li","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jgh.14746","article-title":"Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population.","volume":"34","author":"Lv","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bpg.2013.06.016","article-title":"Liver abnormalities in connective tissue diseases.","volume":"27","author":"De Santis","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2169\/internalmedicine.52.9458","article-title":"Liver dysfunction in patients with systemic lupus erythematosus.","volume":"52","author":"Takahashi","year":"2013","journal-title":"Internal Med (Tokyo, Japan)"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00296-010-1581-4","article-title":"Systemic lupus erythematosus and autoimmune hepatitis.","volume":"31","author":"Efe","year":"2011","journal-title":"Rheumatol Int"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis.","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cld.2018.12.007","article-title":"Rheumatologic diseases and the liver.","volume":"23","author":"Gebreselassie","year":"2019","journal-title":"Clin Liver Dis"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.amjms.2016.10.014","article-title":"Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis).","volume":"353","author":"Adiga","year":"2017","journal-title":"Am J Med Sci"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/0961203316655210","article-title":"Autoimmune gastrointestinal complications in patients withsystemic lupus erythematosus: case series and literature review.","volume":"25","author":"Alves","year":"2016","journal-title":"Lupus"},{"key":"R15-20250918","first-page":"9","article-title":"Consensus on the diagnosis and management of autoimmune hepatitis (2015).","volume":"32","year":"2016","journal-title":"J Clin Hepatol"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ajg.2015.139","article-title":"Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis.","volume":"110","author":"Dhaliwal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R17-20250918","first-page":"42","article-title":"Guidelines on the diagnosis and management of autoimmune Hepatitis (2021).","volume":"38","year":"2022","journal-title":"J Clin Hepatol"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1002\/art.20622","article-title":"Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events.","volume":"50","author":"Toloza","year":"2004","journal-title":"Arthritis Rheumatism"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/0961203313492578","article-title":"Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity.","volume":"22","author":"Stojan","year":"2013","journal-title":"Lupus"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:02:17Z","timestamp":1758232937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":19,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043570","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"2025-02-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}